Curaleaf Holdings (CURLF) Non-Current Debt (2019 - 2025)

Curaleaf Holdings (CURLF) posted quarterly Non-Current Debt of $512.9 million for Q4 2025, up 9.86% year-on-year from $466.9 million in Q4 2024, and up 9.86% on a QoQ basis from $466.9 million in Q4 2024.

Curaleaf Holdings (CURLF) Non-Current Debt (2019 - 2025) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Non-Current Debt for 7 consecutive years, with $512.9 million the latest figure, recorded in Q4 2025.

  • Quarterly Non-Current Debt rose 9.86% year-over-year to $512.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $512.9 million (up 9.86% YoY) and the FY2025 annual result came in at $512.9 million, up 9.86% from the prior year.
  • Non-Current Debt grew to $512.9 million in Q4 2025 per CURLF's latest filing, from $466.9 million in the prior quarter.
  • Over the last five years, Non-Current Debt for CURLF reached as high as $582.0 billion in Q1 2022 and fell as low as $335.3 million in Q1 2021.
  • A 5-year average of $39.2 billion and a median of $512.9 million in 2025 frame the typical range for Non-Current Debt.
  • Annual changes were most pronounced in 2022 — Non-Current Debt soared 173458.09% — and 2024, when it slipped 14.84%.
  • Year by year, Non-Current Debt stood at $457.9 million in 2021, then climbed by 24.65% to $570.8 million in 2022, then retreated by 3.94% to $548.3 million in 2023, then decreased by 14.84% to $466.9 million in 2024, then advanced by 9.86% to $512.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods registered $512.9 million, $466.9 million, and $461.5 million for Q4 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 10.34 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 14.02 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 9.05 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 27.86 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 12.41 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 3.74 Bn
10 Curaleaf Holdings 7.13 Bn 7.13 Bn 157.29 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 512.92 Mn
Dec 31, 2024 466.90 Mn
Sep 30, 2024 461.48 Mn
Jun 30, 2024 460.32 Mn
Dec 31, 2023 548.29 Mn
Sep 30, 2023 522.38 Mn
Jun 30, 2023 525.60 Mn
Dec 31, 2022 570.79 Mn
Sep 30, 2022 597.18 Mn
Jun 30, 2022 584.95 Mn
Mar 31, 2022 581.98 Bn
Dec 31, 2021 457.92 Mn
Sep 30, 2021 340.25 Mn
Jun 30, 2021 336.45 Mn
Mar 31, 2021 335.32 Mn
Dec 31, 2020 285.00 Mn
Sep 30, 2020 273.70 Mn
Dec 31, 2019 87.95 Mn